CD276 and neoplasm: Our work reinforces and expands those findings beyond proof of concept in a different, clinically relevant disease model, but unlike ROR1 SynNotch CARs, GD2-B7H3 T cells show significant efficacy and survival benefits in a very aggressive tumor model.